GENEMEDICS APP
GENEMEDICS NUTRITION
Potential Health Benefits of Retatrutide
Retatrutide is most commonly used for weight loss or diabetes. It may also improve blood pressure and quality of life.
- Aids in weight reduction [1-7]
- Improves blood glucose levels [2-7]
- Improves blood pressure [5, 7]
Key Takeaways of Retatrutide
- Retatrutide shows promise to be the best weight loss medication currently available including popular fat loss medications Semaglutide (brand names Ozempic, Wegovy, Rybelsus) and Tirzepatide (brand name Mounjaro).
- Retatrutide was created by the pharmaceutical company Eli Lilly to treat obesity and diabetes.
- Retatrutide affects certain biological pathways related to metabolism, appetite regulation, and fat storage, leading to a reduction in body weight.
- Clinical trials and studies have demonstrated that retatrutide can result in significant weight loss when used as part of a comprehensive weight management program.
- Apart from weight loss, Eli Lilly’s retatrutide may offer additional health benefits, such as improvements in insulin sensitivity, cardiovascular risk factors, and overall quality of life.
- Before starting retatrutide for treating obesity, consult with a healthcare professional. Regular monitoring, adherence to prescribed dosages, and healthy lifestyle adjustments are essential for achieving and maintaining the desired outcomes.
What is Retatrutide?
Retatrutide, a new medication created by the pharmaceutical company Eli Lilly, has a major potential for treating obesity and diabetes. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy. When combined with proper diet, regular exercise, and lifestyle modifications, retatrutide can help improve weight loss outcomes and treat comorbidities related to obesity such as diabetes or hypertension (high blood pressure).
How Retatrutide Works?
- Gastric inhibitory polypeptide receptor (GIPR) agonist: As a GIP receptor agonist, retatrutide enhances appetite suppression and prevents fat accumulation, resulting in decreased energy intake and increased energy expenditure.
- Glucagon-like peptide 1 receptor (GLP-1R) agonist: Retatrutide reduces body weight by improving blood sugar levels via enhanced insulin release from the pancreas and reduced release of glucagon (a hormone that increases blood sugar).
- Glucagon receptor (GR) agonist: Retatrutide decreases glucagon release to improve blood sugar levels, decrease food intake, and increase energy expenditure which ultimately results in weight loss.
Chemical Structure of Retatrutide
Retatrutide Clinical Trials
A. Aids in Weight Reduction
Trial results show promising insights into the potential of retatrutide for addressing obesity and various weight-related conditions:
- In a phase 2 trial published in the New England Journal of Medicine on June 26, 2023, 338 obese adults with a body mass index of 30 were enrolled. [1] The primary endpoint was the percentage change in body weight from baseline to 24 weeks. The secondary endpoint encompassed the percentage change in body weight from baseline to 48 weeks, as well as achieving weight reduction of 5% or more, 10% or more, or 15% or more. After 48 weeks, the groups who received a weekly injection of retatrutide showed varying percentages of change in mean weight reduction: -8.7% for the 1-mg group, -17.1% for the combined 4-mg group, -22.8% for the combined 8-mg group, and -24.2% for the 12-mg group (highest dose), in contrast to -2.1% observed in the placebo group. Improvements in LDL-cholesterol, triglycerides, fasting glucose, insulin levels, total cholesterol, HbA1c, as well as systolic and diastolic blood pressure were also observed.
- In adults (aged 20-70 years) with type 2 diabetes for at least 3 months, the administration of retatrutide at 3/6/9/12 mg resulted in robust reductions in body weight with an acceptable safety profile. After nine months, the participants also lost an average of 17% of their body weight. Combining glucagon receptor agonism with GIP and GLP-1 receptor agonism may be one of the reasons retatrutide showed its potent weight loss effects. [2]
- In high-fat-fed mice, twice daily administration of retatrutide for 21 days decreased body weight and nonfasting blood sugar levels and increased circulating insulin concentrations in the blood. [3]
- In mice with obesity, the administration of retatrutide (LY3437943) decreased body weight, improved blood sugar control, and increased energy expenditure. [4]
- In forty-five healthy human subjects, the three highest doses of subcutaneous (under the skin) administration of retatrutide produced a statistically significant weight loss that was maintained up to day 43. [5]
- In diet-induced obese mice, retatrutide reduced appetite and body weight by 45% via reduced fat mass, making it superior to other GIPR and GLP-1R agonists. [6]
-
In patients with type 2 diabetes (T2D) and obesity, subcutaneous administration of retatrutide for 12 weeks resulted in reductions in body weight of up to 8.96 kg with a safety and tolerability profile similar to other incretins (weight loss peptides). [7]
B. Improves Blood Sugar Levels
Retatrutide improves blood sugar levels through its effects on the hormones insulin and glucagon. Insulin lowers blood sugar levels while glucagon increases blood sugar levels to achieve homeostasis or balance. As a GLP-1 agonist and GR agonist, retatrutide enhances insulin release from the pancreas while reducing glucagon release. This in turn helps achieve healthy blood sugar levels.
Evidence from retatrutide trials suggests that the medication can produce beneficial effects on the blood sugar levels of people with diabetes and uncontrolled blood sugar:
- In adults (aged 20-70 years) with T2D for at least 3 months, the administration of retatrutide at 3/6/9/12 mg resulted in robust reductions in blood sugar levels with an acceptable safety profile compared with placebo treatment. [2]
- In high-fat-fed mice, twice daily administration of retatrutide for 21 days decreased nonfasting blood sugar levels by increasing circulating insulin concentrations in the blood. [3]
-
In obese mice, the administration of retatrutide improved blood sugar control and increased energy expenditure which persisted up to day 43. [4]
- In forty-five healthy human subjects, the three highest doses of subcutaneous administration of retatrutide resulted in increased mean fasting insulin and C-peptide, with maximum levels observed at 24 and 48 hours, which in turn lowered blood sugar levels. [5]
- In diet-induced obese mice, retatrutide lowered blood sugar and insulin levels, indicating improved insulin sensitivity (the body’s response to the effects of insulin). [6]
- In patients with T2D, subcutaneous administration of retatrutide for 12 weeks decreased glycated hemoglobin, also known as HbA1c and is a measure of blood sugar, with a higher safety and tolerability profile. [7]
C. Improves Blood Pressure
As a weight loss drug, retatrutide can help improve blood pressure by treating obesity. By decreasing energy intake and increasing energy expenditure, retatrutide can promote fat loss. Evidence suggests that weight loss is associated with blood pressure reduction. [8-10] This indicates that retatrutide may be beneficial in people with hypertension.
Studies support the blood pressure-lowering effects of retatrutide:
- A Phase 1 retatrutide clinical trial, which is the first human study assessing the safety and tolerability of single-ascending doses of retatrutide (LY3437943), included forty-five healthy subjects who were randomized to receive subcutaneous LY3437943 (6 rising dose levels) or placebo. [5] During the treatment period, important data such as vital signs, electrocardiogram (ECG), laboratory data, and adverse events were monitored. Fasting insulin, C-peptide, weight, and appetite were also measured. Results showed that the subjects who received retatrutide had significant weight loss, increased insulin levels, and decreased systolic blood pressure (returned to near baseline by Day 29).
- A Phase 1 proof-of-concept study assessed the safety and tolerability of several ascending doses of retatrutide in patients with T2D. [7] In this study, seventy-two diabetic patients were randomized to receive retatrutide or placebo. During the treatment, the researchers assessed vital signs, laboratory data, and adverse events. After 12 weeks, the group that received retatrutide had decreases in blood pressure with a higher safety and tolerability profile compared to the placebo group.
Associated Side Effects of Retatrutide
Retatrutide side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on retatrutide. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of retatrutide. Despite this, it was listed as a side effect associated with retatrutide even though these associated side effects are very uncommon.
Side effects associated with retatrutide may include the following:
- Chest pain
- Depression
- Difficulty breathing
- Dizziness
- Dry mouth
- Fatigue
- Headache
- Irregular heartbeat
- Swelling in the hands and feet
With regard to safety, the most common adverse events were related to the gastrointestinal system. These side effects are mild in nature and go away on their own. As a result, the safety and tolerability profile of retatrutide aligns with other incretin-based therapies (hormones produced by the gut that help regulate blood sugar levels).
Retatrutide Dosage
Retatrutide is a new drug for obesity that is currently being developed by Eli Lilly. The initial dose of retatrutide is 0.5 mg, which is injected subcutaneously once weekly. The dose of the drug can be increased to 1 mg, 2 mg, or 4 mg after 4 weeks, depending on the patient’s response. The maximum dose is 12 mg per week.
The initial dose of retatrutide is important because it helps to minimize the risk of side effects. If the patient tolerates the initial dose well, the dose can be increased gradually. However, if the patient experiences any serious side effects, the dose of the drug should be reduced or discontinued.
Retatrutide Weight Loss Before and After Results
About Dr. George Shanlikian
Dr. George Shanlikian, renowned as the world’s best hormone therapy doctor, possesses expertise in various medical domains. These include Bio-Identical Hormone Replacement Therapy, Peptide Replacement Therapy, Anti-Aging Medicine, Regenerative Medicine, Stress Management, Nutrition Consulting, Nutritional Supplement Consulting, and Exercise Consulting.
Read more about him here: https://www.genemedics.com/dr-george-shanlikian-md-best-hormone-therapy-doctor
Read more success stories here:
Men’s Success Stories: https://www.genemedics.com/about-ghi/ghi-success-stories/mens-success-stories/
Women’s Success Stories: https://www.genemedics.com/about-ghi/ghi-success-stories/womens-success-stories/
FAQ
When will retatrutide be available?
Retatrutide is currently in phase 3 clinical trial. This trial by Eli Lilly and company will evaluate the safety and efficacy of the medication in participants with obesity and cadiovascular disease. Velocity Clinical Research is currently recruiting participants for a phase 3 clinical trial of retatrutide.
Eli Lilly is also assessing the safety and efficacy of retatrutide for chronic weight management and in patients with knee osteoarthritis and obstructive sleep apnea, as part of its TRIUMPH Phase III development program. The TRIUMPH-3 clinical trial for retatrutide began in April 2022 and enrolled adults with obesity who are at high risk for cardiovascular disease or heart disease. It focuses on treating obesity and its complications comprehensively.
What is retatrutide and how does it work?
Retatrutide belongs to the class of drugs known as glucagon-like peptide-1 (GLP-1) agonists, much like Wegovy and Ozempic. However, it distinguishes itself by acting on two additional hormones: glucose-dependent insulinotropic polypeptide (GIP), which aids in blood sugar management, and glucagon, which can help suppress appetite and increase energy expenditure.
Who manufactures retatrutide?
Retatrutide is currently in Phase III of clinical development for the treatment of obesity, with Eli Lilly and company leading the research efforts.
Is retatrutide the same as tirzepatide?
No, retatrutide and tirzepatide are not the same. They are both medications being studied for obesity and diabetes treatment, but they work in slightly different ways in the body to achieve similar goals of controlling blood sugar levels and promoting weight loss.
What is the difference between Mounjaro and retatrutide?
Mounjaro (generic name is tirzepatide) is a GLP-1 receptors agonista that mimics the effects of a hormone called glucagon-like peptide-1 (GLP-1). It helps people feel full and satisfied after eating, and it also helps to lower blood sugar levels. On the other hand, retatrutide is a triple GLP-1 receptors agonist that mimics the effects of GLP-1, GIP, and https://www.ncbi.nlm.nih.gov/books/NBK551568/ glucagon. It is thought to be more effective than Mounjaro at helping people lose weight.
Blog
Retatrutide and Blood Sugar Control: An Effective Strategy for Managing Diabetes
Introduction:-
Diabetes is a chronic condition that affects millions of people worldwide. It requires careful management to prevent complications and maintain a good quality of life. One emerging strategy in diabetes management is the use of retatrutide, a novel medication that has shown promise in effectively controlling blood sugar levels. In this blog post, we will explore retatrutide’s mechanism of action, its benefits for blood sugar control, and its potential as a valuable tool in managing diabetes.
Improving Your Metabolic Health with Retatrutide: An In-Depth Analysis
Introduction :
Metabolic health plays a crucial role in overall well-being, and its optimization is especially important for individuals with conditions like diabetes and obesity. Retatrutide, a novel medication, has garnered attention for its potential in improving metabolic health. In this blog post, we will delve into the mechanisms of action of retatrutide, explore its impact on various metabolic parameters, and discuss its potential as a valuable tool for enhancing metabolic health.
Retatrutide: Transforming Lives through Weight Loss and Blood Sugar Control
Introduction :
In the fight against obesity and diabetes, finding effective strategies to achieve weight loss and maintain optimal blood sugar control is crucial. Retatrutide, a groundbreaking medication, has emerged as a transformative tool that offers hope for individuals struggling with weight management and diabetes. This blog post explores the multifaceted benefits of retatrutide, its impact on weight loss, its role in blood sugar control, and how it is revolutionizing the lives of countless individuals.
Maximizing Weight Loss with Retatrutide: Tips and Strategies
Introduction :
Retatrutide, a revolutionary medication, has emerged as a powerful tool for weight loss. By suppressing appetite and aiding in satiety, it supports individuals in achieving their weight loss goals. In this blog post, we will explore various tips and strategies to maximize weight loss while using retatrutide. These recommendations, when combined with the medication’s effects, can help individuals optimize their weight loss journey and achieve long-term success.
How Retatrutide Can Help Manage Comorbidities of Obesity
Introduction :
Obesity is a complex condition that often leads to various comorbidities, such as type 2 diabetes, cardiovascular disease, and metabolic syndrome. Effectively managing these comorbidities is crucial for overall health and well-being. Retatrutide, a novel medication, has shown promise not only in promoting weight loss but also in managing the comorbidities associated with obesity. In this blog post, we will explore how retatrutide can help manage the comorbidities of obesity, its mechanisms of action, and its potential as a valuable tool in improving overall health outcomes.
Unlocking the Health Benefits of Retatrutide: A Comprehensive Guide
Introduction :
Retatrutide, a revolutionary medication, has gained attention for its potential health benefits across various conditions. From weight management to diabetes control and cardiovascular health, retatrutide offers a comprehensive approach to improving overall well-being. In this blog post, we will explore the extensive health benefits of retatrutide, its mechanisms of action, and its potential as a valuable tool in enhancing health outcomes.
References
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972. Epub ahead of print. PMID: 37366315.
- Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England), 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5.
- Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013). A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. The Journal of biological chemistry, 288(49), 35581–35591. https://doi.org/10.1074/jbc.M113.512046.
- Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., Pirro, V., Wainscott, D. B., Willard, F. S., Abernathy, M., Morford, L., Du, Y., Benson, C., Gimeno, R. E., Haupt, A., & Milicevic, Z. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and fat loss: From discovery to clinical proof of concept. Cell metabolism, 34(9), 1234–1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013.
-
Available from https://diabetesjournals.org/diabetes/article/70/Supplement_1/104-OR/139575/104-OR-Novel-GIP-GLP-1-Glucagon-Receptor-Agonist.
- Available from https://diabetesjournals.org/diabetes/article/70/Supplement_1/679-P/140585..
- Available from https://diabetesjournals.org/diabetes/article/71/Supplement_1/340-OR/146500/340-OR-LY3437943-LY-a-Novel-Triple-GIP-GLP-1.
- Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003). Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension (Dallas, Tex.: 1979), 42(5), 878–884. https://doi.org/10.1161/01.HYP.0000094221.86888.AE.
- Bacon, S. L., Sherwood, A., Hinderliter, A., & Blumenthal, J. A. (2004). Effects of exercise, diet and weight loss on high blood pressure. Sports medicine (Auckland, N.Z.), 34(5), 307–316. https://doi.org/10.2165/00007256-200434050-00003.
- Fantin, F., Giani, A., Zoico, E., Rossi, A. P., Mazzali, G., & Zamboni, M. (2019). Weight Loss and Hypertension in Obese Subjects. Nutrients, 11(7), 1667. https://doi.org/10.3390/nu11071667.
Success Stories
before after
At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old
Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer
Call 800-277-4041 for a Free Consultation
- Usually takes 15-30 minutes
- Completely confidential
- No obligation to purchase anything
- We will discuss your symptoms along with your health and fitness goals
- Free post-consult access for any additional questions you may have
© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.